Ngā hua rapu kaituhi

1

Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors mā Patricia LoRusso

I whakaputaina 2016

Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
2

Review: Targeting the Hedgehog pathway in cancer mā Sachin Gupta, Naoko Takebe, Patricia LoRusso

I whakaputaina 2010

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
3

Targeting the epidermal growth factor receptor mā B. F. El-Rayes, Patricia LoRusso

I whakaputaina 2004

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
4

The Intersection of Immune-Directed and Molecularly Targeted Therapy in Advanced Melanoma: Where We Have Been, Are, and Will Be mā Ryan J. Sullivan, Patricia LoRusso, Keith T. Flaherty

I whakaputaina 2013

Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
5

BET inhibitors: a novel epigenetic approach mā Deborah Blythe Doroshow, J.P. Eder, Patricia LoRusso

I whakaputaina 2017

Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
6

Clinical experience of MEK inhibitors in cancer therapy mā Ding Wang, Scott A. Boerner, James D. Winkler, Patricia LoRusso

I whakaputaina 2006

Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
7

Pharmacometabolomics Reveals Irinotecan Mechanism of Action in Cancer Patients mā Xun Bao, Jianmei Wu, Seongho Kim, Patricia LoRusso, Jing Li

I whakaputaina 2018

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
8

Next-Generation Sequencing to Guide Clinical Trials mā Lillian L. Siu, Barbara A. Conley, Scott A. Boerner, Patricia LoRusso

I whakaputaina 2015

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
9

A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer mā Elaina M. Gartner, Paula Silverman, Michael S. Simon, Lawrence E. Flaherty, Judith Abrams, Percy Ivy, Patricia LoRusso

I whakaputaina 2011

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
10

AZD1480: A Phase I Study of a Novel JAK2 Inhibitor in Solid Tumors mā Elizabeth R. Plimack, Patricia LoRusso, Patricia McCoon, Weifeng Tang, Annetta Krebs, Gregory A. Curt, Sabine Eckhardt

I whakaputaina 2013

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
11

Clinical Pharmacokinetics and Exposure‐Toxicity Relationship of a Folate‐<i>Vinca</i> Alkaloid Conjugate EC145 in Cancer Patients mā Jing Li, Edward A. Sausville, Patrick Klein, David Morgenstern, Christopher P. Leamon, Richard A. Messmann, Patricia LoRusso

I whakaputaina 2009

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
12

Targeted Morphoproteomic Profiling of Ewing's Sarcoma Treated with Insulin-Like Growth Factor 1 Receptor (IGF1R) Inhibitors: Response/Resistance Signatures mā Vivek Subbiah, Aung Naing, Robert Brown, Helen Chen, L. Austin Doyle, Patricia LoRusso, Robert S. Benjamin, Pete Anderson, Razelle Kurzrock

I whakaputaina 2011

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
13

Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study mā Patricia LoRusso, Anthony F. Shields, Shirish M. Gadgeel, Ulka N. Vaishampayan, Tina Guthrie, Thomas A. Puchalski, John Xu, Qi Liu

I whakaputaina 2010

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
14

Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer mā Ian E. Krop, Shanu Modi, Patricia LoRusso, Mark D. Pegram, Ellie Guardino, Betsy Althaus, Dan Lu, Alexander Strasak, Anthony Elias

I whakaputaina 2016

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
15

$Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors$

Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors mā Christina M. Annunziata, Elise C. Kohn, Patricia LoRusso, Nicole Houston, Robert L. Coleman, Manuela Buzoianu, Gabriel J. Robbie, Robert J. Lechleider

I whakaputaina 2012

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
16

Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma mā Aung Naing, Patricia LoRusso, Siqing Fu, David S. Hong, H. X. Chen, L. Austin Doyle, Alexandria T. Phan, Mouhammed Amir Habra, Razelle Kurzrock

I whakaputaina 2013

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
17

A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors mā Renata Ferrarotto, Gail Eckhardt, Akash Patnaik, Patricia LoRusso, L. Faoro, John V. Heymach, Ann M. Kapoun, Lu Xu, P.N. Munster

I whakaputaina 2018

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
18

$Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors$

Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors mā Aung Naing, Patricia LoRusso, Siqing Fu, David S. Hong, Pete Anderson, Robert S. Benjamin, Joseph A. Ludwig, Helen X. Chen, L. Austin Doyle, Razelle Kurzrock

I whakaputaina 2012

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
19

Differentiation and Definition of Vascular-Targeted Therapies mā Dietmar W. Siemann, Michael C. Bibby, G. Dark, Adam P. Dicker, Ferry A.L.M. Eskens, Michael R. Horsman, Dieter Marmé, Patricia LoRusso

I whakaputaina 2005

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
20

Efficacy and Safety of the MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series mā Noboru Yamamoto, Anthony W. Tolcher, Navid Hafez, Iwona Ługowska, Rodryg Ramlau, Teresa Macarulla, Junxian Geng, Jian Li, Michael Teufel, Angela Märten, Patricia LoRusso

I whakaputaina 2024

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:

Ngā hua rapu - Patricia LoRusso

Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors mā Patricia LoRusso

Review: Targeting the Hedgehog pathway in cancer mā Sachin Gupta, Naoko Takebe, Patricia LoRusso

Targeting the epidermal growth factor receptor mā B. F. El-Rayes, Patricia LoRusso

The Intersection of Immune-Directed and Molecularly Targeted Therapy in Advanced Melanoma: Where We Have Been, Are, and Will Be mā Ryan J. Sullivan, Patricia LoRusso, Keith T. Flaherty

BET inhibitors: a novel epigenetic approach mā Deborah Blythe Doroshow, J.P. Eder, Patricia LoRusso

Clinical experience of MEK inhibitors in cancer therapy mā Ding Wang, Scott A. Boerner, James D. Winkler, Patricia LoRusso

Pharmacometabolomics Reveals Irinotecan Mechanism of Action in Cancer Patients mā Xun Bao, Jianmei Wu, Seongho Kim, Patricia LoRusso, Jing Li

Next-Generation Sequencing to Guide Clinical Trials mā Lillian L. Siu, Barbara A. Conley, Scott A. Boerner, Patricia LoRusso

A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer mā Elaina M. Gartner, Paula Silverman, Michael S. Simon, Lawrence E. Flaherty, Judith Abrams, Percy Ivy, Patricia LoRusso

AZD1480: A Phase I Study of a Novel JAK2 Inhibitor in Solid Tumors mā Elizabeth R. Plimack, Patricia LoRusso, Patricia McCoon, Weifeng Tang, Annetta Krebs, Gregory A. Curt, Sabine Eckhardt

Clinical Pharmacokinetics and Exposure‐Toxicity Relationship of a Folate‐<i>Vinca</i> Alkaloid Conjugate EC145 in Cancer Patients mā Jing Li, Edward A. Sausville, Patrick Klein, David Morgenstern, Christopher P. Leamon, Richard A. Messmann, Patricia LoRusso

Targeted Morphoproteomic Profiling of Ewing's Sarcoma Treated with Insulin-Like Growth Factor 1 Receptor (IGF1R) Inhibitors: Response/Resistance Signatures mā Vivek Subbiah, Aung Naing, Robert Brown, Helen Chen, L. Austin Doyle, Patricia LoRusso, Robert S. Benjamin, Pete Anderson, Razelle Kurzrock

Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study mā Patricia LoRusso, Anthony F. Shields, Shirish M. Gadgeel, Ulka N. Vaishampayan, Tina Guthrie, Thomas A. Puchalski, John Xu, Qi Liu

Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer mā Ian E. Krop, Shanu Modi, Patricia LoRusso, Mark D. Pegram, Ellie Guardino, Betsy Althaus, Dan Lu, Alexander Strasak, Anthony Elias

Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors mā Christina M. Annunziata, Elise C. Kohn, Patricia LoRusso, Nicole Houston, Robert L. Coleman, Manuela Buzoianu, Gabriel J. Robbie, Robert J. Lechleider

A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors mā Renata Ferrarotto, Gail Eckhardt, Akash Patnaik, Patricia LoRusso, L. Faoro, John V. Heymach, Ann M. Kapoun, Lu Xu, P.N. Munster

Differentiation and Definition of Vascular-Targeted Therapies mā Dietmar W. Siemann, Michael C. Bibby, G. Dark, Adam P. Dicker, Ferry A.L.M. Eskens, Michael R. Horsman, Dieter Marmé, Patricia LoRusso

Ngā utauta rapu:

Ngā marau whai pānga